Damien Mikael Hansra

Damien Mikael Hansra

Auto-generated profile, based on publicly available information

Damien Mikael Hansra

Cancer Treatment Centers of America, Atlanta, GA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AAAjjai S. Alva
Ajjai S. Alva
PMPam K. Mangat
Pam K. Mangat
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
Susan HalabiSusan Halabi
Susan Halabi
DHDamien Hansra
Damien Hansra
RSRichard L. Schilsky
Richard L. Schilsky
PURPOSE: The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort of patients with metastatic breast cancer (mBC) with high tumor mutational burden (HTMB) treated with pembrolizumab are reported. METHODS: Patients with advanced mBC received standard doses of either 2 mg/kg or 200 mg infusions of pembrolizumab every 3 weeks. Simon's two-stage design was used with a primary study end point of disease control (DC) defined as objective response or stable disease of at least 16 weeks duration. If two or more patients in stage I achieved DC, the cohort would enroll 18 additional patients in stage II. Secondary end points include progression-free survival (PFS), overall survival, and safety. RESULTS: Twenty-eight patients were enrolled from October 2016 to July 2018. All patients' tumors had HTMB ranging from 9 to 37 mutations/megabase. DC and objective response were noted in 37% (95% CI, 21 to 50) and 21% of patients (95% CI, 8 to 41), respectively. Median PFS was 10.6 weeks (95% CI, 7.7 to 21.1); median overall survival was 30.6 weeks (95% CI, 18.3 to 103.3). No relationship was observed between PFS and tumor mutational burden. Five patients experienced ≥ 1 serious adverse event or grade 3 adverse event at least possibly related to pembrolizumab consistent with the product label. CONCLUSION: Pembrolizumab monotherapy has antitumor activity in heavily pretreated patients with mBC characterized by HTMB. Our findings support the recent US Food and Drug Administration approval of pembrolizumab for treatment of patients with unresectable or metastatic solid tumors with HTMB without alternative treatment options.

1 January 2018 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
DHD. M. Hansra
D. M. Hansra
KMK. McIntyre
K. McIntyre
JRJ. Ramdial
J. Ramdial
SSS. Sacks
S. Sacks
CPC. S. Patrick
C. S. Patrick
EAE. Ahn
E. Ahn
Evidence regarding opinions on integrative modalities by patients and physicians is lacking. Methods. A survey study was conducted assessing how integrative modalities were valued among hematology/oncology patients and hematologists and oncologists at a major tertiary medical center. Results. 1008 patients and 55 physicians were surveyed. With the exception of support groups, patients valued nutrition services, exercise therapy, spiritual/religious counseling, supplement/herbal advice, support groups, music therapy, and other complimentary medicine services significantly more than physicians (P ≤ 0.05). Conclusion. With the exception of support groups, patients value integrative modalities more than physicians. Perhaps with increasing education, awareness, and acceptance by providers and traditional institutions, integrative modalities could be equally valued between patients and providers. It is possible that increased availability and utilization of integrative oncology modalities at tertiary hospital sites could improve patient satisfaction, quality of life, and other clinical endpoints.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DHDamien Mikael Hansra
Damien Mikael Hansra
E21671 Background: Dronabinol, synthetic delta-9-tetrahydrocannabinol (Δ-9-thc), is the active compound & natural occuring component of Cannabis Sativa L(Marijuana). Dronabinol is used as an appetite stimulant & treatment of chemo induced nausea/vomiting in cancer patients (pts). Here we evaluate the efficacy, safety, & other clinical endpoints in older cancer pts. Methods: Survey study administered to cancer pts prescribed Dronabinol w/ 7 questions (yes/no/n/a): Did Dronabinol increase appetitie? decrease nausea/vomiting? improve mood? decrease insomnia? decrease anxiety? have any side effects? improve quality of life (QOL)? Also pts were asked if they preferred sythetic meds vs natural plant based meds (oil, capsule, liquid, etc). Inclusion: age > 60, hem/onc malignancy, prescribed Dronabinol. Exclusion: death, altered mental status, not taking Dronabinol, off label use. Unpaired t-test w/ two sided P value used to compare differences. Results: N = 28 pts enrolled, 12 pts excluded, 16 pts meeting study criteria. Mean age 70 (range 61-78). 100% white pts w/ 94% Latin 6% non-Latin. 50% male 50% female. 81% Onc vs 19% Heme malignancy. Dose given: 2.5 mg QD (25%), 2.5 mg BID (62.5%), 5mg BID (12.5%). Significant improvements in appetite (87.5% vs 12.5% p = < 0.0001), anxiety (75% vs 25% p = 0.0128), QOL (81.3% vs 18.7% p = 0.0001) observed. No side effects seen in 87.5 % vs 12.5% (dizziness) p = < 0.0001 of pts. 100% vs 0%, p = < 0.0001 of pts preferred natural plant based meds vs synthetics. Non significant improvements in mood (61.5% vs 38.5% p = 0.2567), insomnia (61.5% vs 38.5% p = 0.2567), nausea/vomiting (71.4% vs 28.6% p = 0.1263) observed. Conclusions: This unique study shows Dronabinol significantly improved appetite, anxiety, & QOL in older cancer pts w/ most pts having no side effects. Also non significant improvements in mood, nausea/vomiting, insomnia observed. 100% of pts preferred natural plant based meds vs. synthetics. Further investigations examining the clinical benefits & safety of Dronabinol & Cannabis Sativa L are warranted in older cancer patients.

1 March 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DHDamien Mikael Hansra
Damien Mikael Hansra
RRRebecca Rollins
Rebecca Rollins
KRKaren Rados
Karen Rados
AJAnita Johnson
Anita Johnson
JRJohnathan Ramey
Johnathan Ramey
RARicardo H. Alvarez
Ricardo H. Alvarez
28 Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) with unique clinical-pathological & prognostic characteristics. Studies have shown obesity to be risk factor for TNBC. Furthermore, patients (pts) with BC and overweight/obesity have a worse prognosis. Here we investigate body mass index (BMI) & weight trends among BC survivors. Methods: A retrospective review BC pts at Cancer Treatment Centers of America Atlanta from 2012-10/27/17. Definition of a survivor: pts who have completed definitive therapy with no evidence of disease. Survivor BMI & weight gain (kg) calculated from chart review. Weight gain in kg was recorded post chemotherapy, at 3, 6, 9, 12 month follow up. Inclusion: Pts with ER-PR-HER2- (TNBC), adults > 18 yo, pts who completed chemo (neoadjuvant or adjuvant) & surgery +/- radiation. Exclusion: Pts who died, had relapsed local disease or metastatic disease; missing BMI data; currently on chemotherapy; who did not receive chemotherapy; missing continuous BMI data or pathology report; lost to follow up. Results: 1756 BC pts with stage IA-IIIC identified, 300 pts identified as TNBC. A total of 134 patients met full inclusion/exclusion survivorship criteria. Average age of survivors = 52 (range 25-76). Stage: I = 38%; II = 50%, III = 12%. BMI categories: 0% underweight (BMI < 18.5 kg/m2), 15% normal weight (BMI 18.5 to < 25 kg/m2), 18% overweight (BMI 25 to < 30 kg/m2), 55% obese (BMI ≤30 kg/m2), 12% morbid obesity (BMI ≤ 40 kg/m2). Average BMI for all survivors = 32.23 +/-0.59 kg/m2 (range 19-52 kg/m2); post chemotherapy weight change = 0.53 +/-0.41 kg; at 3 month follow up = -0.16 +/-0.51 kg; at 6 month = -0.02 +/-0.54 kg; at 9 month follow up 1.20 +/-0.59 kg; at 12 month follow up = 2.25 +/-0.61 kg. BMI by stage: I = 32.81 +/- 1.00 kg/m2; II = 32.12 +/- 0.91 kg/m2; III = 32.44 +/- 1.27 kg/m2. Conclusions: In our study, female survivors with TNBC present with obesity and gain weight after chemotherapy. Also, weight gain continues at 9 & 12 months post definitive treatment. Survivors with TNBC should be treated with intensive weight loss interventions given that overweight/obesity is a risk factor for recurrence, worse prognosis, & cardiovascular events.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EMEleanor Meisner
Eleanor Meisner
RRRebecca Rollins
Rebecca Rollins
JEJoe Ensor
Joe Ensor
AMAmber Moran
Amber Moran
AWAmanda Woodward
Amanda Woodward
RARicardo H. Alvarez
Ricardo H. Alvarez
1074 Background: A recent Phase III study in MBC with gBRCAm, olaparib monotherapy provided a statistical significant and clinically meaningful PFS benefit compared to standard physician of choice treatment. (Robson M, NEJM 2017) Recently, olaparib was FDA approved for MBC with gBRCAm. Methods: IRB-approved analysis of pts underwent to genomic or genetic analysis. Retrospective review charts for pts with MBC who had received ≥2 chemotherapy lines for MBC were tested with genomic or genetic studies. The objective of this analysis was to determine the PFS2/PFS1 ratio. [von Hoff DD, 2014]. lBRCAm were detected in 12 out 19 pts [8 Foundation One, 3 Foundation Act and 1 Guardant 360] where somatic versus germline nature was not determined and gBRCAm 7 out 19 pts. Results: From 03/2014 to 08/2017, 319 pts with advanced cancer were treated with targeted therapy based on molecular abnormality. Overall 19 out 319 (6%) consisted on olaparib for MBC with gBRCAm or lBRCAm. Median age 45.1 years (range, 31-67), 18 out 19 pts were female, 14/19 were Caucasians, median number of previous lines of treatment for MBC was 4 (range, 2-8). Olaparib was dosed at 300 mg po bid until disease progression. A total of 12 out 19 pts (63%) the PFS ratio was ≥ 1.3, with a Wilson score 95% CI of (0.7, 3.). Nine out 12 pts (75%) with lBRCAm had increased PFS ratio. The 6-month PFS was 69.4% [95% CI: (40%, 86.4%)], and the 6-month OS was 88.8% [95% CI: (62.1%, 97.1%)] There was no Grade 3-4 toxicity. Conclusions: Olaparib monotherapy provided a statistically significant increment of PFS in almost 2/3 (63%) of heavily pretreated MBC pts harboring gBRCAm and lBRCAm. Interestingly, 75% of patients with lBRCAm resulted in improvement the PFS with minimal toxicity. Further research is necessary to extend the olaparib approval for lBRCAm in MBC pts.

5 November 2014 in International Cancer Conference Journal
Verified
Journal Article
Closed access
PDF file
DHDamien M. Hansra
Damien M. Hansra
MPMario Ponce
Mario Ponce
JSJose David Sandoval-Sus
Jose David Sandoval-Sus
MCMaureen Cioffi-Lavina
Maureen Cioffi-Lavina
RPRavi Patel
Ravi Patel
Edgardo S. Santos, MD, FACP, FASCOEdgardo S. Santos, MD, FACP, FASCO
Edgardo S. Santos, MD, FACP, FASCO